ReShape Lifesciences Inc. RSLS
Set alert
3.92 0.00 0.00%
At close · Aug 14
2.80 Day range 4.65
7.48 52-week range 1,660.09
- YTD
- -99.12%
- 1 year
- -99.62%
- Open
- 3.06
- Prev close
- 3.92
- Mkt cap
- 2.34M
- Vol
- 13.59M
- Avg vol
- 3.32M
- EPS
- -108.27
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.80
- High
- 4.65
- Forward P/E
- -11.83
- Beta
- 1.35
- Short ratio
- 0.22
- Inst. own
- 1.83%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.39
- 200-d avg
- 9.00
- 1y target
- 0.00
Financial health
Altman Z-Score
-12.12 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Valuation
P/E -3.3×
FY 2016 5y median -1.1× FY 2025
P/S 106×
FY 2016 5y median 1.1× FY 2025
P/B 9.0×
FY 2016 5y median 1.6× FY 2025
P/FCF -9.0×
FY 2016 5y median -2.1× FY 2025
EV/EBITDA -10.6×
FY 2016 5y median -0.8× FY 2025
EV/Sales 90.5×
FY 2016 5y median 1.2× FY 2025
FCF Yield -11.1%
FY 2016 5y median -48.1% FY 2025
Profitability
Gross Margin 68.4%
FY 2016 5y median 63.2% FY 2025
Operating Margin -859.2%
FY 2016 5y median -183.3% FY 2025
Net Margin -3209.7%
FY 2016 5y median -411.2% FY 2025
ROE -272.8%
FY 2016 5y median -170.9% FY 2025
ROIC -72.4%
FY 2016 5y median -219.9% FY 2025
ROA -157.9%
FY 2016 5y median -148.8% FY 2025
Growth (YoY)
Revenue -96.0%
FY 2016 FY 2025
Operating Income 64.5%
FY 2016 FY 2025
EPS (diluted) 98.6%
FY 2016 FY 2025
Free Cash Flow 15.3%
FY 2016 FY 2025
Financial Health
Current Ratio 2.0×
FY 2016 5y median 2.0× FY 2025
Quick Ratio 2.0×
FY 2016 5y median 1.7× FY 2025
Debt / Equity 0.0×
FY 2016 5y median 0.0× FY 2025
Net Debt / EBITDA 1.8×
FY 2016 5y median 0.3× FY 2025
Interest Coverage -18.7×
FY 2016 5y median -18.7× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31